Drug Profile
SLV 301
Latest Information Update: 15 Oct 2002
Price :
$50
*
At a glance
- Originator Solvay
- Class
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 15 Oct 2002 Discontinued - Preclinical for Schizophrenia in Netherlands (unspecified route)
- 08 Dec 2000 New profile
- 08 Dec 2000 Preclinical development for Schizophrenia in Netherlands (Unknown route)